Therapeutic Efficacy of Intravenously Administered Transferrin-Conjugated Dendriplexes on Prostate Carcinomas
Authors:
- 1 March 2014
- journal article
- Published by Taylor & Francis in Nanomedicine
- Vol. 9 (4) , 421-434
Abstract
Aim: Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anticancer t...Keywords
This publication has 33 references indexed in Scilit:
- Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery systemBiomaterials, 2012
- Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplexBiomaterials, 2011
- Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNAJournal of Controlled Release, 2010
- Transcriptionally regulated, prostate-targeted gene therapy for prostate cancerAdvanced Drug Delivery Reviews, 2009
- Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogueMolecular Cancer Therapeutics, 2008
- IL-12 Plasmid Delivery by in Vivo Electroporation for the Successful Treatment of Established Subcutaneous B16.F10 MelanomaMolecular Therapy, 2002
- Prostate-Specific Antigen Response and Systemic T Cell Activation After In Situ Gene Therapy in Prostate Cancer Patients Failing RadiotherapyHuman Gene Therapy, 2001
- Cytopathic effect of in situ gene therapy in prostate cancerHuman Pathology, 2000
- Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literatureProstate Cancer and Prostatic Diseases, 1999
- THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune ResponsesAnnual Review of Immunology, 1998